Rules-Based Medicine (RBM) offers a broad menu of proteins associated with various processes in the development of cancer, including oncogenesis, immune or inflammatory responses, cell proliferation and metabolites secreted from tumor tissue. Our protein biomarkers are selected using peer-reviewed research and aim to expedite development of targeted cancer therapeutics. We offer multiplexed Luminex® assays, ultrasensitive Simoa® assays and the Olink® Target 48 Cytokine panel. RBM also offers TruCulture®, our proprietary whole blood collection and culture system.
Download Document